Loading patent…
AssigneesBaker Norton Pharmaceuticals, Inc., The United States of America as represented by the Department of Health and Human Services
InventorsGary E. Striker, Liliane J. Striker, Kenneth H. Kortright
Estimating the term…
A method of preventing, reducing or reversing nephrotoxicity or renal dysfunction induced by administration of a cyclosporin or tacrolimus to a mammalian patient. The method comprises the co-administration to the patient, either before, together with or after cyclosporin or tacrolimus administration, of a pharmaceutical composition containing an effective amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable salt thereof. The oral route of administration is preferred. The total daily dosage of PPS or PPS salt ranges from about 2 to about 50 mg/kg of patient body weight, or about 140 to about 3,500 mg per day in adult human patients. Also disclosed are a method of providing immunosuppressive therapy to a patient while avoiding cyclosporin or tacrolimus-induced nephrotoxicity, and combination pharmaceutical compositions to be used in such therapy.
A method of preventing nephrotoxicity or renal dysfunction involving fibrotic lesions or scarring in the kidney interstitium induced by administration of a cyclosporin or tacrolimus to a mammalian patient, said method comprising co-administration to the patient of a pharmaceutical composition containing an effective nephrotoxicity-reducing amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable salt thereof.
A method of providing immunosuppressive therapy to a mammalian patient in need of such therapy while preventing or reducing the development of nephrotoxicity or renal dysfunction involving fibrotic lesions or scarring in the kidney interstitium said method comprising co-administration to the patient of an effective immunosuppression-inducing amount of a cyclosporin or tacrolimus and an effective nephrotoxicity-reducing amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition containing an effective immunosuppression-inducing amount of an immunosuppressive agent selected from the group consisting of a cyclosporin or tacrolimus and an effective nephrotoxicity-reducing amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.